|
David S. Tierney M.D. was elected to NexMed's Board of Directors in January 2007. Dr. Tierney was most recently President and Chief Executive Officer of Valera Pharmaceuticals Inc. (Nasdaq: VLRX) and served in that position from August 2000 until April 2007 at which time Valera merged with Indevus Pharmaceuticals Inc. Prior to joining Valera Dr. Tierney was President of Biovail Technologies a division of Biovail Corporation. While there Dr. Tierney had responsibility for all of Biovail's research and development regulatory and clinical activities. Prior to Biovail Dr. Tierney spent three years at Roberts Pharmaceutical Corporation as Senior Vice President of Drug Development with responsibility for all research and development activities and overall responsibility for drug development medical affairs worldwide regulatory affairs and chemical process development as well as being part of the executive management team. Prior to joining Roberts Dr. Tierney spent eight years at Elan Corporation in a variety of management positions. Currently he serves on the Board of Directors of Bioject Medical Technologies (Nasdaq: BJCT) and Catalyst Pharmaceutical Partners Inc. (Nasdaq: CPRX). Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin Ireland and was trained in internal medicine. | 